Cargando…

Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis

OBJECTIVES: Treatment beyond progression (TBP) is defined as treatment continuing in spite of disease progression, according to the Response Evaluation Criteria In Solid Tumors. We performed a systematic review and meta-analysis to provide evidence for the effects of TBP on lung cancer survival. MAT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuo, Wei-Ke, Weng, Ching-Fu, Lien, Yin-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713814/ https://www.ncbi.nlm.nih.gov/pubmed/36465371 http://dx.doi.org/10.3389/fonc.2022.1023894

Ejemplares similares

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression
por: Van Assche, Katrijn, et al.
Publicado: (2014)

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xu, Yanjun, et al.
Publicado: (2021)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
por: Tartarone, Alfredo, et al.
Publicado: (2021)

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis
por: Xu, Linrui, et al.
Publicado: (2022)

Strategies of Dose Escalation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer: Image Guidance and Beyond
por: Chi, Alexander, et al.
Publicado: (2014)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Qian, Xiaohan, et al.
Publicado: (2021)

Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis
por: Wang, Min, et al.
Publicado: (2015)

Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Wenhua, et al.
Publicado: (2021)

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yin, et al.
Publicado: (2022)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan
por: Tsai, Chang-Hung, et al.
Publicado: (2020)

Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis
por: Li, Feng, et al.
Publicado: (2022)

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis
por: Yang, Yin, et al.
Publicado: (2022)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

CT-Based Sarcopenic Nomogram for Predicting Progressive Disease in Advanced Non-Small-Cell Lung Cancer
por: Yi, Xiaoping, et al.
Publicado: (2021)

The Role of Prophylactic Cranial Irradiation in Patients With Non-small Cell Lung Cancer: An Updated Systematic Review and Meta-Analysis
por: Liu, Lipin, et al.
Publicado: (2020)

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
por: Ni, Yunfeng, et al.
Publicado: (2023)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis
por: Wang, Yanning, et al.
Publicado: (2020)

Suppression of EGFR/PKC-δ/NF-κB Signaling Associated With Imipramine-Inhibited Progression of Non-Small Cell Lung Cancer
por: Yueh, Po-Fu, et al.
Publicado: (2021)

CALR-TLR4 Complex Inhibits Non-Small Cell Lung Cancer Progression by Regulating the Migration and Maturation of Dendritic Cells
por: Chen, Ruo, et al.
Publicado: (2021)

Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol
por: Li, Feng, et al.
Publicado: (2018)

Detection of KRAS mutation using plasma samples in non-small-cell lung cancer: a systematic review and meta-analysis
por: Cai, Peiling, et al.
Publicado: (2023)

Effectiveness and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis
por: Qiao, Chenxi, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review
por: Zhang, Chuan, et al.
Publicado: (2022)

Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Inhibition of RNF182 mediated by Bap promotes non-small cell lung cancer progression
por: Liu, Yating, et al.
Publicado: (2023)

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer
por: Wang, Yanning, et al.
Publicado: (2022)

Hsa_circ_0001946 Inhibits Lung Cancer Progression and Mediates Cisplatin Sensitivity in Non-small Cell Lung Cancer via the Nucleotide Excision Repair Signaling Pathway
por: Huang, Ma-Sha, et al.
Publicado: (2019)

Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Nan, et al.
Publicado: (2022)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Prophylactic Cranial Irradiation in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Al Feghali, Karine A., et al.
Publicado: (2018)

Prognostic Value of the Geriatric Nutritional Risk Index in Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
por: Wang, Haoyu, et al.
Publicado: (2022)

Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3784kkcbou6fcpa7n7hc3jfvon